Difference between revisions of "PRAME"
Jump to navigation
Jump to search
| (2 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
==General== | ==General== | ||
*PRAME is an acronym for ''PReferentially expressed Antigen in MElanoma''. | |||
==Positive staining== | ==Positive staining== | ||
*80-85% of primary melanomas.<ref name=pmid30045064/> | *80-85% of primary melanomas.<ref name=pmid30045064/> | ||
*85-90% of metastatic melanomas.<ref name=pmid30045064/> | *85-90% of metastatic melanomas.<ref name=pmid30045064/> | ||
Pattern:<ref>{{cite journal |authors=Lezcano C, Jungbluth AA, Busam KJ |title=PRAME Immunohistochemistry as an Ancillary Test for the Assessment of Melanocytic Lesions |journal=Surg Pathol Clin |volume=14 |issue=2 |pages=165–175 |date=June 2021 |pmid=34023098 |pmc=8152939 |doi=10.1016/j.path.2021.01.001 |url=}}</ref> | |||
*Nuclear staining. | |||
==See also== | ==See also== | ||
| Line 14: | Line 18: | ||
[[Category:Immunohistochemistry]] | [[Category:Immunohistochemistry]] | ||
[[Category: Abbreviation]] | |||
Latest revision as of 21:23, 4 March 2025
PRAME is an immunostain that is typically positive in malignant melanoma.[1]
General
- PRAME is an acronym for PReferentially expressed Antigen in MElanoma.
Positive staining
Pattern:[2]
- Nuclear staining.
See also
References
- ↑ Jump up to: 1.0 1.1 1.2 Lezcano C, Jungbluth AA, Nehal KS, Hollmann TJ, Busam KJ (November 2018). "PRAME Expression in Melanocytic Tumors". Am J Surg Pathol 42 (11): 1456–1465. doi:10.1097/PAS.0000000000001134. PMC 6631376. PMID 30045064. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631376/.
- ↑ Lezcano C, Jungbluth AA, Busam KJ (June 2021). "PRAME Immunohistochemistry as an Ancillary Test for the Assessment of Melanocytic Lesions". Surg Pathol Clin 14 (2): 165–175. doi:10.1016/j.path.2021.01.001. PMC 8152939. PMID 34023098. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152939/.